HWH-340

Primary objective: To preliminarily evaluate the anti-tumor effect of multiple doses of HWH340 tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) with germline or somatic BRCA1/2 mutations based on the imaging changes assessed by the investigator (according to RECIST 1.1 and PCWG3 criteria). Secondary objectives: To preliminarily evaluate the effect of HWH340 tablets in reducing serum PSA in patients with mCRPC; to preliminarily explore the effect of HWH340 tablets on pain and quality of life in patients with mCRPC; to preliminarily evaluate the safety and tolerability of HWH340 tablets in patients with mCRPC.